Literature DB >> 27241038

Changing Pattern of Sedative Use in Older Adults: A Population-Based Cohort Study.

Andrea Iaboni1,2,3, Susan E Bronskill4,5, Katelyn B Reynolds6, Xuesong Wang4, Paula A Rochon4,5,7,8, Nathan Herrmann6,9, Alastair J Flint10,6.   

Abstract

BACKGROUND: Benzodiazepine medications have well-documented side effects, and their prescription rates in older adults have been declining. Trazodone and quetiapine are medications with sedative properties when used at low doses and are commonly used off-label for sleep or behavioral symptoms in older adults.
OBJECTIVE: Our objective was to describe the shifting patterns of sedative prescription in older adults over time by comparing changes in benzodiazepine, trazodone, and quetiapine dispensing between community and long-term care settings.
METHODS: We conducted a population-based serial cross-sectional study to compare the patterns of sedative dispensing (specifically, benzodiazepines, trazodone, and quetiapine) to individuals aged ≥66 years between 1 January 2002 and 31 March 2013 in Ontario, Canada. We compared rates of use between long-term care and community settings and used linear regression models to characterize the magnitude and direction of the rate of change in sedative use by age, sex, and dementia status.
RESULTS: The dispensing of trazodone and quetiapine increased over time, and this coincided with a decrease in benzodiazepine dispensing. This pattern was particularly apparent in the oldest cohort and in those with dementia. Benzodiazepines, trazodone, and quetiapine were associated with high rates of psychotropic polypharmacy. Overall trends were similar in long-term care and the community.
CONCLUSIONS: While benzodiazepine prescribing is declining among older adults in Ontario over time, there is a corresponding shift towards low-dose, off-label prescribing of trazodone and quetiapine and psychotropic polypharmacy. These prescribing trends highlight sedative substitution and reinforce the need to confirm efficacy and safety of this practice.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27241038     DOI: 10.1007/s40266-016-0380-3

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  49 in total

1.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2015-10-08       Impact factor: 5.562

Review 2.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine.

Authors:  M H Beers; J G Ouslander; I Rollingher; D B Reuben; J Brooks; J C Beck
Journal:  Arch Intern Med       Date:  1991-09

3.  Transforming healthcare in Ontario through integration, evidence, and building capacity for improvement.

Authors:  Ben Chan
Journal:  Healthc Manage Forum       Date:  2012

4.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

5.  Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project.

Authors:  Consuelo Huerta; Victoria Abbing-Karahagopian; Gema Requena; Belén Oliva; Yolanda Alvarez; Helga Gardarsdottir; Montserrat Miret; Cornelia Schneider; Miguel Gil; Patrick C Souverein; Marie L De Bruin; Jim Slattery; Mark C H De Groot; Ulrik Hesse; Marietta Rottenkolber; Sven Schmiedl; Dolores Montero; Andrew Bate; Ana Ruigomez; Luis Alberto García-Rodríguez; Saga Johansson; Frank de Vries; Raymond G Schlienger; Robert F Reynolds; Olaf H Klungel; Francisco José de Abajo
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-07-07       Impact factor: 2.890

6.  Mental health-related drug utilization among older adults: prevalence, trends, and costs.

Authors:  Muhammad Mamdani; Mark Rapoport; Kenneth I Shulman; Nathan Herrmann; Paula A Rochon
Journal:  Am J Geriatr Psychiatry       Date:  2005-10       Impact factor: 4.105

7.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

Review 8.  American Geriatrics Society identifies another five things that healthcare providers and patients should question.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2014-02-27       Impact factor: 5.562

Review 9.  Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.

Authors:  M Haria; A Fitton; D McTavish
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

10.  Did the new French pay-for-performance system modify benzodiazepine prescribing practices?

Authors:  Cédric Rat; Gaëlle Penhouet; Aurélie Gaultier; Anicet Chaslerie; Jacques Pivette; Jean Michel Nguyen; Caroline Victorri-Vigneau
Journal:  BMC Health Serv Res       Date:  2014-07-11       Impact factor: 2.655

View more
  15 in total

1.  Detecting and Managing Neuropsychiatric Symptoms in Dementia.

Authors:  Andrea Iaboni; Mark J Rapoport
Journal:  Can J Psychiatry       Date:  2017-03       Impact factor: 4.356

2.  Psychotropic drugs for the behavioural and psychological symptoms of dementia: no free ride.

Authors:  Elia Abi-Jaoude; Nathan M Stall; Paula A Rochon
Journal:  CMAJ       Date:  2018-11-26       Impact factor: 8.262

3.  Benzodiazepine Use in Older Adults in the United States, Ontario, and Australia from 2010 to 2016.

Authors:  Jonathan Brett; Donovan T Maust; Zach Bouck; Rosalinda V Ignacio; Graham Mecredy; Eve A Kerr; Sacha Bhatia; Adam G Elshaug; Sallie A Pearson
Journal:  J Am Geriatr Soc       Date:  2018-02-12       Impact factor: 5.562

4.  Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study.

Authors:  Andrea Iaboni; Michael A Campitelli; Susan E Bronskill; Christina Diong; Matthew Kumar; Laura C Maclagan; Tara Gomes; Mina Tadrous; Colleen J Maxwell
Journal:  CMAJ Open       Date:  2019-09-23

Review 5.  A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia.

Authors:  Maryse Lapeyre-Mestre
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

6.  Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study.

Authors:  Jennifer A Watt; Tara Gomes; Susan E Bronskill; Anjie Huang; Peter C Austin; Joanne M Ho; Sharon E Straus
Journal:  CMAJ       Date:  2018-11-26       Impact factor: 8.262

7.  Changes in Australian Early-Career General Practitioners' Benzodiazepine Prescribing: a Longitudinal Analysis.

Authors:  Parker Magin; Amanda Tapley; Adrian J Dunlop; Andrew Davey; Mieke van Driel; Elizabeth Holliday; Simon Morgan; Kim Henderson; Jean Ball; Nigel Catzikiris; Katie Mulquiney; Neil Spike; Rohan Kerr; Simon Holliday
Journal:  J Gen Intern Med       Date:  2018-07-23       Impact factor: 5.128

Review 8.  Sleep and Long-Term Care.

Authors:  Lichuan Ye; Kathy C Richards
Journal:  Sleep Med Clin       Date:  2017-11-22

9.  Point Prevalence Survey of Benzodiazepine and Sedative-Hypnotic Drug Use in Hospitalized Adult Patients.

Authors:  Heather L Neville; Mia Losier; Jennifer Pitman; Melissa Gehrig; Jennifer E Isenor; Laura V Minard; Ellen Penny; Susan K Bowles
Journal:  Can J Hosp Pharm       Date:  2020-06-01

10.  Prevalence of Central Nervous System-Active Polypharmacy Among Older Adults With Dementia in the US.

Authors:  Donovan T Maust; Julie Strominger; H Myra Kim; Kenneth M Langa; Julie P W Bynum; Chiang-Hua Chang; Helen C Kales; Kara Zivin; Erica Solway; Steven C Marcus
Journal:  JAMA       Date:  2021-03-09       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.